3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Neoplasms
4
Venous Thrombosis
2
Venous Thromboembolism
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Thrombosis
1
Thromboembolism
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Dyskinesias
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
78
Fluorouracil
27
Oxaliplatin
24
130-nm albumin-bound paclitaxel
24
Leucovorin
18
Capecitabine
15
Albumin-Bound Paclitaxel
15
S 1 (combination)
14
Taxes
12
Irinotecan
11
pembrolizumab
9
folfirinox
9
Radiosurgery
9
Radiotherapy
7
Drug Therapy
7
Cisplatin
7
irinotecan sucrosofate
6
Pancreaticoduodenectomy
5
Paclitaxel
5
Injections
5
Docetaxel
5
Blood Specimen Collection
5
apatinib
4
Radiofrequency Ablation
4
Radiation
4
Biopsy
4
tislelizumab
3
rubitecan
3
nimotuzumab
3
camrelizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Pancreatic Neoplasms
×
Rivaroxaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled